CXCL4 suppresses tolerogenic immune signature of monocyte-derived dendritic cells

Abbreviations: HV: healthy volunteer · moDC: monocyte-derived dendritic cells · DCs: dendritic cells · TLR: toll-like receptor

CXCL4 is a chemokine that is known to modulate DC functions and has been implicated in cancer and autoimmunity. Previously, we showed that exposure to CXCL4 drives moDCs to a semi-mature phenotype and function [3]. Here, we cultured monocytes from five healthy volunteers (HV) with IL-4 and GM-CSF to differentiate into moDCs or with IL-4, GM-CSF, and CXCL4 to differentiate into moDCs (CXCL4-moDCs). We performed RNA sequencing analysis on day 6 cultured moDCs and CXCL4-moDCs (see Supporting Information for details). We observed that genes associated with immunogenic DC responses such as CD86, CD83, HLA-A, CCR7, CCL17, FSCN1, LAMP3, SOD2, CD40, and ICAM1 were upregulated on CXCL4-moDCs. Interestingly, the expression of CSF1 receptor (CSF1R), which is downregulated in inflammatory DCs [4], was downregulated on CXCL4-moDCs (Fig. 1A, Supporting Information Fig. S1A). CD80, a co-stimulatory molecule associated with response to stimuli, was not differentially expressed (Supporting Information Fig. S1A). Moreover, genes associated with DC tolerogenicity such as IL10, SLAMF1, STAB1, and CTSC were hypermethylated in CXCL4-moDCs and exhibited negative correlations between RNA expression and DNA methylation levels (Supporting Information Fig. S3A and B). However, it was not the same case for other tolerogenic genes (F13A1, STAB1, and SMAD3). Interestingly, no immunogenic gene exhibited significant negative correlation with the other tolerogenic genes. In fact, among all tolerogenic genes, C1QA, C1QB, and C1QC genes exhibited the strongest negative correlation with most of the immunogenic markers. Additional validation showed that CXCL4 diminished C1q protein expression (Fig. 1D) and CXCL4-moDCs released lower amounts of C1q in comparison to moDCs (Fig. 1E).

Changes in DNA methylation have been associated with aberrant gene expression and autoimmune disorders [6]. CXCL4 induced hypermethylation in the promoter regions of all 3 C1q (C1QA, C1QB, C1QC) genes and in the gene body of C1QB and C1QC genes (Fig. 2A–C). All these hypermethylated regions were strongly negative correlated with the corresponding gene’s expression (Fig. 2D–F). Additionally, we found that CXCL4 drives hypermethylation of individual CpGs across the C1QA, C1QB, and C1QC genes, and exhibits strong negative correlated with the corresponding gene’s expression (Supporting Information Fig. S2A–C).

Other genes associated with tolerogenic responses including IL10, SLAMF1, STAB1, and CTSC were hypermethylated in CXCL4-moDCs and exhibited negative correlations between RNA expression and DNA methylation levels (Supporting Information Fig. S3A and B). However, it was not the same case for other tolerogenic genes (F13A1, STAB1, and SMAD3). Interestingly, no immunogenic gene exhibited significant negative correlation between RNA expression and DNA methylation levels (data not shown). Thus, CXCL4 mediates epigenetic modifications and transcriptional suppression of tolerogenic markers (especially C1q) to tip the balance between immunogenic and tolerogenic DCs.
Figure 1. CXCL4 drives dramatic up-regulation of immunogenic signature and down-regulation of tolerogenic markers, inclusively C1q. (A) Heat map showing immunogenic and tolerogenic gene signatures. The colour scheme represents gene expression and is shown as Z-scores. (B) Expression of C1QA, C1QB, and C1QC genes on moDCs and CXCL4-moDCs. \( n = 5 \) Healthy Volunteer or HV. Likelihood ratio test. \( \text{**} P < 0.01 \). (C) Pearson correlation analysis between the expression of C1QA, C1QB, and C1QC genes (black text) and tolerogenic (red text) or immunogenic (blue text) signature genes. Color scheme gradient and pie graphs represent the correlation coefficients between comparisons. Data shown for 5 HV, all from independent experiments. (D) Western blot analysis of C1q and tubulin. Representative blot of 4 HV is shown (4 independent experiments). Below, we show the quantification for 4 HV. Paired t-test. \( \text{*} P < 0.05; \text{**} P < 0.005 \). (E) Measurement of soluble C1q by Elisa \( n = 11 \) HV, 8 independent experiments). Paired t-test. \( \text{**} P < 0.005 \).
Figure 2. CXCL4 exposure during moDC differentiation associates with strong hypermethylation of C1q. DNA methylation analysis between moDCs and CXCL4-moDCs of C1QA (A), C1QB (B), and C1QC (C) regions (1500 and 200 bp upstream of the transcription start site (TSS); 5’ untranslated region (UTR), and first exon) (n = 5 HV). Likelihood ratio test. *P < 0.005. Correlation between differently methylated (D) C1QA, (E) C1QB, (F) C1QC regions and their corresponding gene expression, respectively. “R” represents Pearson correlation and “p” represents p-value calculated by t-test. Data shown for 5 HV, all from independent experiments.

Binding of C1q, the first component of the classical pathway of complement system, to PAMPs and apoptotic cell fragments results in the initiation of the complement system cascade and cell activation. C1q also functions as an opsonin that enables the detection and phagocytosis of PAMPs and apoptotic cell fragments either directly, or indirectly via binding to secreted antibodies and C-reactive protein (CRP). Immature DCs and macrophages are able to secrete high levels of C1q in contrast to monocytes, mature DCs and T-cells [7]. Primary C1q deficiency in humans [8] and C1q KO mice [9] have been shown to result in autoimmune conditions such as systemic lupus erythematosus (SLE).
C1q has been consistently shown to be up-regulated on tolerogenic DCs [1,2,10]. Inflammatory triggers were shown to diminish C1q production during DC maturation [7]. Here, we revealed for the first time that CXCL4 exposure epigenetically modified promoters of several tolerogenic markers, including C1q genes and repressed expression of C1q genes. Thus, CXCL4 suppresses tolerogenic DC phenotype and boosts immunogenic responses, and we elucidated C1q as a critical factor in CXCL4-driven autoimmune diseases.

Sandra C. Silva-Cardoso*,1,2 Weiyang Tao*,1,2 Beatriz Malvar Fernández1,2, Marianne Boes1,3, Timothy R.D.J. Radstake1,2, and Aridaman Pandit1,2

References

1) Schinnerling, K., García-González, P. and Aguillón, J. C., Gene expression profiling of human monocyte-derived dendritic cells - searching for molecular regulators of tolerogenicity. Front. Immunol. 2015. 6: 528.

2) Navarro-Barriuso, J., Mansilla, M. J. and Martínez-Cáceres, E. M., Searching for the transcriptomic signature of immune tolerance induction-biomarkers of safety and functionality for tolerogenic dendritic cells and regulatory macrophages. Front. Immunol. 2018.9: 2062.

3) Silva-Cardoso, S. C., Affandi, A. J., Spel, L., Gossu, M., van Roon, J. A. G., Boes, M. and Radstake, T. R. D. J., CXCL4 exposure potentiates TLR-driven polarization of human monocyte-derived dendritic cells and increases stimulation of T cells. J. Immunol. 2017. 199: 253–262.

4) Rieppsaaene, J., van Oudenaren, A., den Broeder, B. J. H., van Ilcken, W. F. J., Pothof, J. and Leenen, P. J. M., MicroRNA-mediated down-regulation of M-CSF receptor contributes to maturation of mouse monocyte-derived dendritic cells. Front. Immunol. 2013. 4: 353.

5) Torres-Aguilar, H., Aguilar-Ruiz, S. R., González-Pérez, G., Munguía, R., Bajaña, S., Meraz-Ríos, M. A. and Sánchez-Torres, G., Tolerogenic dendritic cells generated with different immunosuppressive cytokines induce antigen-specific anergy and regulatory properties in memory CD4+ T cells. J. Immunol. 2010. 184: 1765–1775.

6) Wang, X., Lei, D., Ding, J., Liu, S., Tao, L., Zhang, F. and Peng, J., A DNA-Methylated

Conflict of interest: The authors declare no financial or commercial conflict of interest.

Keywords: C1q • CXCL4 • DNA methylation • Monocyte-derived dendritic cells • RNA sequencing

Acknowledgments: This work was supported by a Ph.D. grant from the Portuguese Fundação para a Ciência e a Tecnologia (SFRH/BD/89643/2012) (to S.C.S.C.); China Scholarship Council (CSC) No. 201606300050 (to W.T.); Netherlands Organisation for Scientific Research (NWO) grant number: 016.Veni.178.027 (to A.P.); ERC Starting grant, a grant from the Dutch Arthritis Foundation and Pre-Seed grant Dutch Association of Science (NWO) (to T.R.D.J.R.).

*These authors contributed equally to this work.